For following the competition: what moved in each program, several studies read as one move.
- ART5803
- efgartigimod alfa
- Allogeneic CRISPR-Cas9 Engineered Anti-CD19 CAR T-cells CTX112
- + 2 more
Mondays · ranked, phase 3 first · readouts ahead · See a sample brief
Add Autoimmune Diseases of the Nervous System to watchlistEvery Monday by email · turn it off any timePro · free during the beta